ECLS | Extracorporeal Membrane Oxygenation

Registry Dashboard of ECMO-Supported COVID-19 Patient Data

Thank you for helping ELSO disseminate information by entering your experience in the ELSO Registry as soon as ECMO is implanted - before the run is complete. Instructions for entering data in the Registry and COVID-19 addendum can be found on the Data Definitions page.

We recognize you cannot complete and submit the entire ELSO Registry case report form prior to completion of the ECMO run and discharge from the hospital, but we would still like to have the data you know now.

To address concerns about incomplete data we report three nested data sets to accommodate the fact that different patients will be at different stages of care (and thus have more or less incomplete data). Also when considering the data please understand that the data displayed is a real-time data stream and subject to change as more patient information is accrued and as centers update the ELSO Registry Case Report Form and the ELSO COVID-19 addendum.



COVID-19 Cases on ECMO in the ELSO Registry

Total COVID-19 Cases COVID-19
Confirmed Cases
16,422
Total counts of COVID-19 confirmed patients.

COVID-19 ECMO counts by ELSO Chapter

Still on ECMO Still Hospitalized at ELSO Center Total (n)
All ELSO 461 769 16,504
          North America 128 223 10,582
          Europe 155 216 3,337
          Asia Pacific 31 62 395
          Latin America 111 203 1,091
          SWAAC 36 65 1,099
Reports counts of ECMO-supported suspected or confirmed COVID-19 cases by ELSO Chapter

Filters affect the data shown in the tables below:

Year To Date

Region

Patient Age


Patients who initiated ECMO at
least 90 days ago
COVID-19
Confirmed
15,096
COVID-19
In-hospital Mortality
48%

Outcomes

Pre-ECMO Patient Factors

Patient-level summaries of COVID ECMO runs. All categorical variables are given as 'percentage (count)'
Total ARDS Cohort
Number cases 15096 11255
Age(years)
Median(IQR) 47(37,56) 48(38,56)
# observed 15096 11255
BMI, kg/m2
Median(IQR) 32(28,37) 32(28,38)
# observed 14052 10460
Sex
Male 69%(10342) 70%(7866)
Female 31%(4750) 30%(3386)
# observed 15092 11252
Race/Ethnicity
Black 11%(1635) 10%(1166)
White (Non-Hispanic) 44%(6646) 43%(4884)
Asian 8%(1281) 8%(898)
Mid East, N African 4%(675) 5%(563)
Other 3%(444) 3%(328)
Unknown 5%(734) 5%(573)
Multiple 5%(750) 6%(635)
Hispanic 19%(2931) 20%(2208)
# observed 15096 11255
Pre-ECMO Comorbidities
No comorbidity 25%(3840) 24%(2720)
Cancer 2%(258) 2%(181)
Pregnancy 4%(623) 4%(474)
Immunocompromised 5%(688) 5%(509)
Diabetes 24%(3571) 25%(2761)
Pre-existing heart disease 4%(603) 3%(315)
Pre-existing lung disease 4%(566) 4%(424)
Pre-existing renal insuff. 3%(440) 3%(311)
Frailty 1%(127) 1%(74)
Asthma 10%(1544) 10%(1180)
BMI $> 30 \mathrm{kg}/\mathrm{m}^2$ 50%(7474) 52%(5834)
Hypertension 31%(4708) 32%(3644)
# observed 15096 11255
Acute illness
ARDS 79%(11911) 100%(11255)
Acute heart failure 8%(1225) 5%(561)
Myocarditis 2%(334) 1%(62)
Acute kidney injury 26%(3974) 27%(3037)
# observed 15096 11255
Pre-ECMO Cardiac Arrest
Yes 6%(925) 3%(335)
No 94%(14031) 97%(10810)
# observed 14956 11145
Pre-ECMO Co-Infection
No Co-infection 49%(7332) 46%(5173)
Bacterial pneumonia 45%(6726) 48%(5384)
Co-viral infection 9%(1413) 9%(1010)
Blood stream infection 18%(2737) 19%(2167)
Urinary tract infection 7%(1124) 8%(931)
# observed 15094 11253

Pre-ECMO Interventions

Support and therapies. All categorical variables are given as 'percentage (count)'
PreECLS PreECLS
Number cases 15096 11255
Noninvasive ventilation
Noninvasive ventilation prior to intubation 77%(11558) 80%(9033)
BiPAP 38%(5776) 41%(4650)
CPAP 13%(1942) 12%(1367)
HFNC 51%(7752) 55%(6211)
# observed 15096 11255
Pre-ECLS intubation (days)
Median(IQR) 2.8(0.8,5.9) 3.2(1.0,6.1)
# observed 12599 9467
Ventilator mode
Conventional 96%(12415) 97%(9558)
# observed 12948 9854
PEEP, cm H2O
Median(IQR) 14.0(10.0,16.0) 14.0(10.0,16.0)
# observed 11506 8898
PIP, cm H2O
Median(IQR) 33.0(30.0,38.0) 34.0(30.0,38.0)
# observed 9236 7101
FiO2
Median(IQR) 1.00(0.95,1.00) 1.00(1.00,1.00)
# observed 11411 8684
PaO2/FiO2
Median(IQR) 70(57,91) 70(57,89)
# observed 11154 8497
PCO2
Median(IQR) 60(49,75) 61(51,75)
# observed 11851 8989
Pre-ECMO Support
Prone positioning 52%(7870) 56%(6326)
# observed 15035 11207
Neuromuscular blockers 68%(10208) 72%(8078)
# observed 15035 11204
Inhaled pulmonary vasodilators 28%(4280) 31%(3479)
# observed 15035 11207
Any vasoactive support 57%(8595) 56%(6248)
# observed 15029 11202
Norepinephrine 51%(7624) 51%(5676)
# observed 15029 11202
Therapies, Immunomodulators
Any therapy 88%(13248) 91%(10214)
Glucocorticoids 79%(11888) 82%(9214)
IVIG 3%(396) 2%(212)
Anti-cytokine 22%(3333) 24%(2732)
Lopinavir/Ritonavir 2%(270) 2%(222)
JAK inhibition 3%(523) 4%(442)
Chloroquine/hydroxychloroquine 7%(1022) 7%(824)
Remdesivir 49%(7368) 52%(5875)
# observed 15096 11255
Support type
Respiratory 93%(14063) 100%(11232)
Cardiac 5%(795) 0%(11)
ECPR 2%(238) 0%(12)
# observed 15096 11255

Patient Status & Complications

Outcomes
Total ARDS Cohort
Last known patient status
Discharged alive to home or acute rehabilitation 26%(3965) 26%(2888)
Discharged alive to long-term acute care or unspecified location 12%(1771) 13%(1433)
Discharged to another hospital 12%(1790) 11%(1257)
Remain in the hospital (discharged from ICU) 0%(9) 0%(6)
Remain in the ICU 0%(66) 0%(42)
In-hospital death 50%(7495) 50%(5629)
Tracheostomy 47%(6415) 51%(5220)
# observed 13731 10268
Select complications
Seizures 1%(113) 1%(82)
# observed 15024 11197
CNS infarction by US/CT/MRI 2%(251) 1%(152)
# observed 15024 11197
CNS hemorrhage by US/CT/MRI 6%(963) 7%(762)
# observed 15024 11197
Hemolysis 7%(1102) 8%(859)
# observed 15024 11197
Oxygenator failure 21%(3131) 23%(2597)
# observed 15024 11197
Pump failure 2%(318) 2%(254)
# observed 15024 11197
Circuit change 11%(1678) 12%(1345)
# observed 15024 11197
Thrombosis/Clots in circuit component 3%(507) 4%(406)
# observed 15024 11197
Discharge location
Home 30%(2294) 30%(1674)
Transfer to LTAC or Rehab
Transfer to another hospital 24%(1790) 23%(1257)
Other/Unknown 6%(428) 5%(300)
*N/A - Data elements with n<5 are not displayed.

ELSO Ownership, No Rights to Publication, Disclaimer

The Dashboard content has been compiled and reported from a variety of sources, is not independently verified by ELSO, and is subject to change without notice. ELSO and its authorized agents and contractors make no representations or warranties about the quality, content, completeness, suitability, adequacy, sequence, accuracy, or timeliness of such content. ELSO disclaims any responsibility for any inaccuracy, whether by inclusion or omission, on the Dashboard or the Site, and disclaims any responsibility for subsequent change or withdrawal of data shown on the Dashboard or the Site, which is subject to alteration without notice. ELSO disclaims any and all warranties regarding this information and all liability whatsoever relating thereto. Any person who uses information obtained from this Dashboard does so at his or her own risk.

The Dashboard is provided as a public service to facilitate real-time sharing of information during the COVID-19 crisis for educational purposes only by health practitioners. ELSO owns the compilation of all data, and its use or publication by any third party is strictly forbidden. Publication or representation of this information as if it were statistically significant or part of a scientific study is irresponsible and misleading.

The tables are consistent with the Lancet Publication article but the data presented here is real time

Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, Bartlett RH, Tonna JE, Hyslop R, Fanning JJ, Rycus PT, Hyer SJ, Anders MM, Agerstrand CL, Hryniewicz K, Diaz R, Lorusso R, Combes A, Brodie D, the Extracorporeal Life Support Organization. Extracorporeal Membrane Oxygenation Support in COVID-19: The Registry Report from the Extracorporeal Life Support Organization. Lancet. 2020; [In Press].

We’ve updated our Privacy Policy. By continuing to use this Service, you acknowledge you’ve read the updated Privacy Policy.